Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy, consisting of a corticosteroid and lidocaine, is being investigated by Aslinur Keles Ercisli, MD, PhD, for the treatment of adhesive capsulitis (frozen shoulder). The formulation typically includes 1 cc of a corticosteroid, 4 cc of 2% lidocaine, and 5 cc of saline, administered via intra-articular injection. The corticosteroid component functions as a glucocorticoid receptor agonist, exerting potent anti-inflammatory effects to reduce joint capsule fibrosis and pain. Lidocaine acts as a local anesthetic by blocking voltage-gated sodium channels, providing immediate symptomatic relief. The clinical research focuses on comparing different injection techniques—anterior, posterior, and combined—to optimize therapeutic outcomes in patients with stage 2 adhesive capsulitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corticosteroid + lidocaine.